Incannex receives final A$5.1M R&D tax refund; 2026 non-dilutive capital tops A$11.2M

Incannex Healthcare Inc.

Received final A$5,102,788.30 refund under Australian R&D Tax Incentive Program on Aug 11, 2026.
Combined with prior A$6,039,162.43, total 2026 non-dilutive proceeds exceed A$11.2 million.
Refund follows approval of overseas findings and amendment of FY25 income tax return.
Funds strengthen debt-free balance sheet; support clinical assets IHL-42X and PSX-001.
Company expects additional R&D tax incentive funding in 2027 for eligible activities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.